*UPDATE* Dr. Boyd Graves AIDS suit goes forward

[Tehuti-4]

UPDATE June 19, 2005 - PRESS RELEASE

U.S. DESPERATELY SEEKING TO DISMISS AIDS ORIGIN LAWSUIT



San Diego, CA. - Federal Judge Sabraw has ordered an open court oral argument for Friday, June 24, 2005 at 1:30p.m.to hear arguments by the United States to support a motion to dismiss the AIDS ORIGIN lawsuit of Dr. Boyd Ed Graves. Dr. Graves AIDS ORIGIN research and his nearly eight years of continuous legal action against the United States for the creation, production and proliferation of HIV/AIDS has been receiving critical acclaim from scientists and medical doctors from all over the world.

I am hopeful, said Graves, that the Federal Court will deny the United States motion to dismiss and allow this issue to reach a jury verdict some time next year. I am certain reasonable people will conclude the U.S AIDS ORIGIN documents require and demand further accountability from the defendant, the United States of America.

Dr. Boyd Ed Graves can be reached at 619-578-3254

Now to the article....

According to the 1971 progress report of the U.S. Special Virus program, HIV/AIDS is a recombinant (virus) agent that has been formed by converging a leukemia and a lymphoma, a BIOLOGOCAL WEAPON.


In 1984, (alleged) co-discoverers of HIV/AIDS, Drs. Robert Gallo and Luc Montagnue, concluded the original name of HIV/AIDS is LEUKEMIA/LYMPHOMA virus. See, Montagnue, L. & Gallo, R.C., et. al., Human T-Cell Leukemia Lymphoma Virus Cold Spring Harbor Laboratory, (Cold Spring Harbor, NY, 1984). Additionally, the United States admits that the Nazi sheep virus visna, had not yet appeared in human disease. Because no one could explain how this Nazi sheep virus supposedly hopped species, the U.S. General Accounting Office began an investigation into the U.S. origin of HIV/AIDS in July, 2001 at the bequest of a Congressman.


The United States has sought to hide, dispel, distract and mislead any serious inquiry into the U.S. Special Virus program at every level and by every means necessary until this litigation.


AIDS co-developer himself, defendant, Robert C. Gallo concluded in a report that HIV/AIDS evolved from Nazi sheep visna virus disease. ( See Gallo, R.C., et. al., Science, Vol. 223, pp. 173 * 177, January, 1985. See also, Proceedings of the United States of America, National Academy of Sciences, Vol. 83, pp. 4007 * 4011, June, 1986, Sonigo, Cell, 1985 Aug 42(1):369 * 362, Nucleotide Sequence of the Visna Lentivirus: Relationship to the HIV/AIDS Virus. )


Proceedings of the United States of America, National Academy of Sciences, ( Vol. 92, pp. 3283 * 3287, April 11, 1995.) outlined the relationship of the Nazi sheep visna virus to the HIV virus.

Now what is interesting is the following:


In 1902, the United States funded the Cold Springs Harbor Laboratory in New York, and two years later they opened the U.S. Station for Experimental Evolution. (Development of Biological Weapons)


In 1910, chickens became the victims of a man made transmissible agent which bears striking homology to HIV/AIDS, the Rous Sarcoma Virus. The U.S. government has had a biological weapons program since 1910. What is even more interesting is that the Nazi sheep visna virus did not exist before 1932. Yes, you got it, the Nazis' developed the first strains and the U. S. Government Biologiocal Weapons program continued on with this deadly virus. It is a recombinant turned into the HIV (virus) agent, formed by converging a leukemia and a lymphomathat according to Dr. Gallo and other researchers.

What is so disturbing also is that a cure for the HIV virus has been held back. On November 14, 1997, the U.S. awarded Rhode Island Company, Marentech, ( the patent is registered to a Marvin S. Antleman, Antleman Technologies Inc., Antlemann licensed it to Marentech ), patent #5676977 for the cure for AIDS. In November, 2001, Boyd Graves who is the Plaintiff in this lawsuit accessed the cure and has been free of prescription drugs for nearly two years. The Plaintiff in the lawsuit and numerous other individuals have taken the drug and have been free of having to take any other HIV/AID prescriptions for two years.

On March 25, 2003, Presidential Executive Order 13292 was issued as a means to prepare itself to further insulate the federal program that made AIDS and keep the truth from the American public. This is a travesty and insult to the American public.


Below is a copy of the actual Federal Court filing, Filed, March 1, 2003 in Los Angeles.

UNITED STATES DISTRICT COURT
SOUTHERN DISTRICT OF CALIFORNIA
BOYD E. GRAVES,
Plaintiff, : Case No. : 02 cv2396
THE UNITED STATES OF AMERICA, : Judge Jeffrey Miller

Defendants & PLAINTIFFS RESPONSE IN OPPOSITION TO THE UNITED STATES (UNTIMELY) MOTION TO ;

NOW COMES plaintiff, Boyd E. Graves, in propria persona who will argue on June 27th, 2003 that the United States motion to dismiss the lawsuit seeking the full disclosure of all United States documents which imply directly or indirectly the United States has developed HIV/AIDS (and other synthetic biological agents) should be denied. The Court should Order the defendant to file an answer to the complaint filed on December 6, 2002 and served on Attorney General John Ashcroft on March 1, 2003 via certified mail.

DEFENDANTS MOTION TO DISMISS IS UNTIMELY

Pursuant to the federal rules of civil procedure, a federal defendant has sixty days (60) in which to file an answer to a complaint or in the alternative a motion to dismiss. In this instant action, defendant chose to file a motion to dismiss in lieu of an answer. For defendant motion to dismiss to be timely, the federal rules require that defendant motion should have been filed no later than May 1, 2003. The record reflects that defendant filed its motion to dismiss on May 5, 2003, on the 64th day. Defendant has failed to respond to the complaint within the time period required by the federal rules. Plaintiff believes the Court inherent equitable power should be exercised by punishing defendant for delay and contumacious conduct and requiring an immediate release of documents as aforementioned. In that defendant motion for dismissal should be rejected, plaintiff believes the Court should entertain the people motion for default judgment against the United States.

BACKGROUND OF PLAINTIFF MOTION FOR DEFAULT JUDGMENT

The intent and plain meaning of the Freedom of Information Act requires the Court to Order the immediate full disclosure of all U.S. documents which imply directly or indirectly the United States has developed HIV/AIDS. The sheer public significance of the truths of this issue demand the truth is known. The voluminous science, medical and U.S. policy decisions in the development of HIV/AIDS can not be overcome with vexing litigation, nor can they be further overlooked by the judicial branch of the United States.

The United States Constitution requires the judicial branch of government to do the people's business, particularly when the other two branches of government have died from their own incestuous ness. The judicial branch of government, specifically the United States attorneys, owes a Constitutional obligation and duty of service to the American people, to stand for the American people in the face of wrongdoing by our government and to blow the whistle !on lawless acts of the government or its employees In this instant action, it is the U.S. attorneys who the Attorney General will assign who will have to deal with the perplexing dichotomy of serving a Constitutional government that seeks to secretly kill its own citizens and others.

Plaintiff believe the U.S. Constitution supports the immediate disclosure of the U.S. Special Virus program and the equivalent U.S. policy decisions to develop HIV/AIDS going back as far as the 1878 U.S. mandate of a U.S. Laboratory of Hygiene. Even today, the laboratories mandate to research diseases of world original has not been fully explained. In 1902, the United States funded the Cold Springs Harbor Laboratory in New York, and two years later they opened the U.S. Station for Experimental Evolution.

In 1910, chickens became the victims of a man made transmissible agent which bears striking homology to HIV/AIDS, the Rous Sarcoma Virus. A genuine issue exists that compels the Court to look at the evidence in favor of the no-moving party. Here, the United States cannot withstand the science and medical evidence of AIDS bioengineering being presented from their own policy decisions, sworn testimony and progress reports of the secret program. Here, the United States must rely on American citizens (U.S. attorneys) to buffer it from the masses of the American citizenry, in our quest for truth and fact. The American citizenry should not remain in the dark as to the antics of a Constitutional government, who on the one hand espouses equality and freedom for all, while at the same time, socially engineering (centralizing) the intelligence to allow for ethnic cleansing and genocide.

Clearly here, the establishment of the true origin and root cause of a mystery plague that has mysteriously ingratiated itself into the human genome within the last eighty years, would significantly impact animal and human medicine and !science for the next thousand years. Without the immediate intervention of the judicial branch of government, entire racial species and ethnic creeds of millions of people could be artificially removed by the ongoing development and continuation of state sponsored ethnic weapons of mass destruction.

HIV/AIDS IS A SYNTHETIC BIOLOGICAL AGENT

According to the 1971 progress report of the U.S. Special Virus program, HIV/AIDS is a recombinant (virus) agent that has been formed by converging a leukemia and a lymphoma. See page 2. The United States concedes that it is seeking to make a candidate human virus. Id. In 1984, (alleged) co-discoverers of HIV/AIDS, Drs. Robert Gallo and Luc Montagnue, concluded the original name of HIV/AIDS is LEUKEMIA/LYMPHOMA virus. See, Montagnue, L. & Gallo, R.C., et. al., Human T-Cell Leukemia Lymphoma Virus Cold Spring Harbor Laboratory, (Cold Spring Harbor, NY, 1984). Additionally, the United States admits that the nazi sheep virus visna, had not yet appeared in human disease. See page 39.

Today, according to all science and medical criteria, HIV/AIDS evolved from nazi sheep visna virus and but for this litigation defendant has yet to explain how visna virus suddenly hopped species in the 1970. In this regard, the U.S. General Accounting Office began an investigation into the U.S. origin of HIV/AIDS in July, 2001 at the bequest of a Congressman.

Last June (2002), the GAO erroneously and inaccurately concluded, without science citations or support, that HIV/AIDS and visna sheep disease had evolved together over thousands of years! However the medical and science evidence clearly shows that visna did not exist prior to 1932 and that there was no visna in human disease as late as 1971.

The United States has sought to hide, dispel, distract and mislead any serious inquiry into the U.S. Special Virus program at every level and by every means necessary until this litigation. It is AIDS co-developer himself, defendant, Robert C. Gallo who also concludes that HIV/AIDS evolved from nazi sheep visna virus disease. See Gallo, R.C., et. al., Science, Vol. 223, pp. 173 * 177, January, 1985. See also, Proceedings of the United States of America, National Academy of Sciences, Vol. 83, pp. 4007 * 4011, June, 1986, Sonigo, Cell, 1985 Aug 42(1):369 * 362, Nucleotide Sequence of the Visna Lentivirus: Relationship to the HIV/AIDS Virus.

Moreover, it is the United States own proceedings which concludes that because of visna (being the causative agent of HIV/AIDS), sheep, not monkeys are the best animal model for the testing of new anti-HIV/AIDS drugs. See, Proceedings of the United States of America, National Academy of Sciences, Vol. 92, pp. 3283 * 3287, April 11, 1995. But for the defendant legal shenanigans to thwart the exposure of the truth about the U.S. creation, production and proliferation of HIV/AIDS, this important public matter would have surfaced long ago.

Plaintiff argues an Order requiring defendant to provide full disclosure of the federal virus development program would immediately begin the irreversible process of removing HIV/AIDS, the U.S. special virus, from the human genome. Equally, full public disclosure would allow for the immediate large scale dissemination of the inexpensive U.S. cure for AIDS, U.S. patent #5676977.

In 1997, the U.S. awarded Rhode Island Company, Marentech the patent for the cure for AIDS. In November, 2001, plaintiff accessed the cure and has been free of prescription drugs for nearly two years. Plaintiff firmly believes that others would greatly benefit from an inexpensive AIDS treatment, patented by the United States as a cure. Also, a review of the conference papers from the VIRUS CANCER symposium held at M.I.T. in 1926 would shed significant science and medical insight surrounding the United States early research into ethnic immune-depletion (suppression) synthetic biological agents. Additionally, plaintiff further believes the United States enacted Executive Order 13292 on March 25, 2003 as a means to prepare itself to further insulate the federal program that made AIDS from the American people.

The plethora of U.S. documents and sworn testimony allow for any trier of fact to conclude the HIV/AIDS pandemic is the result of concerted science and medical efforts on the part of the United States and others to achieve a contagious cancer that selectively kills.

WHEREFORE; plaintiff prays the Court will deny defendant motion to dismiss and grant his motion for default judgment by ordering the immediate disclosure of all documents and records which imply a laboratory birth of HIV/AIDS, both directly and indirectly.

Respectfully submitted,

Boyd E. Graves
4486 38th Street, Unit #1
San Diego, CA
92116619-281-8401CERTIFICATE OF SERVICE,

I, Boyd E. Graves, do herby certify that I served a copy of plaintiff response inopposition to defendant motion to dismiss on:

John C. Ashcroft
Carol C. LawBeth
L. Levine
United States Attorneys Civil Division
880 Front Street St. Room 6293
San Diego, CA 92101-8893

Sent this 24th day of May 2003, via first class mail, postage prepaid.__________________________
Boyd E. Graves,
J.D.-------------------Cell - 619-204-5683
Email - boyded2002@yahoo.com
Web - http://www.boydgraves.com
Toll free - (800) 523-2372 Ext. 13046




--------------------------------------------------------------------------------

Will we get the truth from the government? Only if you as citizens start writing your Congressman today.

Here are your:
U. S. Senators
House of Representatives


Now that you have read these shocking facts, what is your opinion. I would like to know, email me

~ God Bless ~



~ David Lawrence Dewey ~ http://www.dldewey.com/may04.htm

[IfasehunReincarnated]

Interesting.

[Jahness]

Greetings Everyone!

I hope he is successful at exposing those bastards.

For many years Dr. Graves has been trying to expose
yt and their crimes against innocent people.

I know it is hard for him since he and very few others
are willing to take the stand against the whole United
SnaKKKes government.

That in an of itself can be very intimidating, so it is good
he has stood stedfast in his studies of this crime, and he
also continues to provide a lot of supporting documents
of the experiments the United Snakes has been doing with
all those diseases, they claim they are studying.

I know under normal circumstances he wouldn't have a chance,
but I think we all might be surprised as to how successful he just
may well be this time. The energies of the planet dictates, all these
wrongs be righted.

May the spirits and the ancestors continue to guide him on
this path he has undertaken to expose these frauds. I really
wish him all the best.

Blessings to All!

[MyBrother'sKeeper]

Greetings Tehuti-4,

I have to say once again, great post. I believe that Dr. Graves will be very successful in exposing YT. What better time than now while in the midst of everything. If this thing goes over well with Graves then I feel it may even pave the way for us to expose YT even more.

[Draptomania]

:cheers: Greetings! Excellent post Bro. Tehuti! Below is the actual patent.



http://patft.uspto.gov/netacgi/nph-P...&RS=PN/5676977

United States Patent 5,676,977
Antelman October 14, 1997

--------------------------------------------------------------------------------
Method of curing AIDS with tetrasilver tetroxide molecular crystal devices


Abstract
The diamagnetic semiconducting molecular crystal tetrasilver tetroxide (Ag.sub.4 O.sub.4) is utilized for destroying the AIDS virus, destroying AIDS synergistic pathogens and immunity suppressing moieties (ISM) in humans. A single intravenous injection of the devices is all that is required for efficacy at levels of about 40 PPM of human blood. The device molecular crystal contains two mono and two trivalent silver ions capable of "firing" electrons capable of electrocuting the AIDS virus, pathogens and ISM. When administered into the bloodstream, the device electrons will be triggered by pathogens, a proliferating virus and ISM, and when fired will simultaneously trigger a redox chelation mechanism resulting in divalent silver moieties which chelate and bind active sites of the entities destroying them. The devices are completely non-toxic. However, they put stress on the liver causing hepatomegaly, but there is no loss of liver function.


--------------------------------------------------------------------------------
Inventors: Antelman; Marvin S. (Rehovot, IL)
Assignee: Antelman Technologies Ltd. (Providence, RI)
Appl. No.: 658955
Filed: May 31, 1996

Current U.S. Class: 424/618; 514/495
Intern'l Class: A61K 033/38
Field of Search: 424/618 514/495



--------------------------------------------------------------------------------

References Cited [Referenced By]

--------------------------------------------------------------------------------

U.S. Patent Documents
4415565 Nov., 1983 Wysor 424/618.
4915955 Apr., 1990 Gomori 424/616.
4952411 Aug., 1990 Fox, Jr. et al. 424/618.
5073382 Dec., 1991 Antelman 424/604.
5078902 Jan., 1992 Antelman 424/618.
5089275 Feb., 1992 Antelman 424/602.
5211855 May., 1993 Antelman 424/618.
5223149 Jun., 1993 Antelman 424/618.
5336499 Aug., 1994 Antelman 424/405.
5571520 Nov., 1996 Antelman 424/618.



Other References
"Is The AIDS Virus A Science Fiction?" by Peter H. Duesberg and Bryan J. Ellison, Policy Review, Summer 1990, pp. 40-51.

Primary Examiner: Hulina; Amy
Attorney, Agent or Firm: Salter & Michaelson

--------------------------------------------------------------------------------

Parent Case Text

--------------------------------------------------------------------------------


This application is a continuation-in-part of patent application Ser. No. 08/310,859 filed Sep. 22, 1994, now abandoned.
--------------------------------------------------------------------------------

Claims

--------------------------------------------------------------------------------


What is claimed is:

1. A method of treating AIDS-afflicted humans comprising injecting a multitude of tetrasilver tetroxide molecular crystals into the bloodstream of the human subject.

2. A method for increasing white blood cell counts in AIDS-afflicted humans comprising injecting a multitude of tetrasilver tetroxide molecular crystals into the bloodstream of the human subject.

3. Methods of treating AIDS-affilicted humans according to claims 1-2 where the concentration of said molecular crystals is approximately 40 PPM of the total blood weight of the human subject.
--------------------------------------------------------------------------------

Description

--------------------------------------------------------------------------------


BACKGROUND OF THE INVENTION

The present invention relates to the employment of molecular crystals as anti-AIDS devices, but more particularly to the molecular crystal semiconductor tetrasilver tetroxide Ag.sub.4 O.sub.4 which has two monovalent and two trivalent silver ions per molecule, and which through this structural configuration enables intermolecular electron transfer capable of killing viruses and binding them to the resulting silver entity so that a single intravenous injection will completely obliterate acquired immune deficiency syndrome (AIDS) in humans. Furthermore, said devices are capable of killing pathogens and purging the bloodstream of immune suppressing moieties (ISM) whether or not created by the AIDS virus (HIV); so as to restore the immune system.

The present invention is based on concepts previously elucidated in applicant's U.S. Pat. No. 5,336,499 which discloses the destruction and inhibition of bacteria, algae and the AIDS virus in nutrient life supporting systems by using said silver oxide devices. Example 3 of said patent discloses that 18 PPM of said crystal devices could totally suppress the AIDS virus (page 6, line 5). Subsequent to the filing of the aforementioned patent, further testing revealed complete 100% destruction of the AIDS virus in vitro at 20 PPM, and the fact that said devices were harmless when ingested and inhaled, being non-toxic.

Encouraged by these evaluations and successes, applicant obtained permission to evaluate the crystals in vitro against murine acquired immune deficiency syndrome (MAIDS). Only one facility in the State of Israel is licensed for these evaluations, namely, the Kaplan Hospital in Rehovot, Israel, which is affiliated with the Hebrew University-Hadassah Medical School where said evaluations were done.

The initial evaluations entailed experimenting with various silver moieties cited in applicant's aforementioned patent, concentrations, non-reactive buffers and modes of administration. After about 18 months of judicious efforts and initial failures, success was finally achieved in destroying the MAIDS virus in C57BL mice with a single intravenous injection. The results of this test program comprise Example 5 of U.S. Pat. No. 5,336,499. After success with mice, the inventor was able to test the efficacy of said devices on two select etiological groups of terminal AIDS patients in a clinic in Tegucigalpa, Honduras, Central America.

The AIDS patients comprised the etiological subgroups, Candidiasis and Wasting Syndrome. Current indicator diseases for diagnosing AIDS which have been expanded by the CDC, fall into the following five major categories with the approximate percent distribution among AIDS patients:


______________________________________
1. P. carinii pneumonia
51%
2. Wasting syndrome
19%
3. Candidiasis 13%
4. Kaposi's sarcoma
11%
5. Dementia 6%
______________________________________



This invention concerns itself with the treatment and cure of candidiasis and wasting syndrome AIDS patients with Tetrasil*. These two groups account for approximately one third of AIDS cases.

*Trademark of Holipharm Corporation (of Israel) for Ag.sub.4 O.sub.4

Stedman's Medical Dictionary (Williams & Wilken's 26th Ed., 1995) defines wasting syndrome "as a condition of 10% weight loss in conjunction with diarrhea or fever . . . Associated with AIDS (p. 1744)."

OBJECTS OF THE INVENTION

The main object of the invention is to provide for a molecular scale device of a single tetrasilver tetroxide crystalline molecule capable of restoring the immunity of AIDS afflicted humans of the two AIDS etiological subgroups, candidiasis and wasting syndrome.

Another object of the invention is to provide for immunity restoration in said AIDS afflicted humans through a single injection.

Another object of this invention is to destroy ISM in humans manifesting AIDS diseases of said AIDS etiological subgroups irrespective as to whether said ISM was HIV induced, since it is known that humans may manifest AIDS and still be HIV negative, and thus restore the immune system in said humans.

Another object of this invention is to destroy the AIDS virus when present in the systems of said AIDS afflicted humans.

SUMMARY OF THE INVENTION

This invention relates to a molecular scale device not only capable of destroying the AIDS virus, but of purging the human bloodstream of pathogens and restoring immunity to AIDS patients of the candidiasis and wasting syndrome categories. Said molecular device consists of a single crystal of tetrasilver tetroxide (Ag.sub.4 O.sub.4). The crystal lattice of this molecule has a unique structure since it is a diamagnetic semiconducting crystal containing two mono and two trivalent silver ions, which in effect are capable of "firing" electrons under certain conditions which will destroy AIDS viruses, other pathogens and immune suppressing moieties (ISM), not only through the electrocution mode, but also by a binding process which occurs simultaneously with electron firing, namely, binding and chelation of divalent silver, i.e., the resulting product of the electron transfer redox that occur when the monovalent silver ions are oxidized and the trivalent ions are reduced in the crystal. The binding/chelation effect occurs at active sites of the AIDS virus, pathogens and ISM. Because of the extremely minute size of a single molecule of this crystal, several million of these devices may be employed in concert to destroy a virus colony to purge a life support system of ISM and pathogens with the consumption of only parts per trillion of the crystal devices. Thus an optimum of 40 PPM of the devices by weight of human blood was found to be sufficient to completely obliterate AIDS. This concentration is slightly over double of the optimum concentration recommended in applicant's aforementioned U.S. patent for the destruction of the human AIDS virus in vitro. Other details concerning the structure of the crystal and its mechanism against pathogens, the AIDS virus and ISM would analogously hold here, and have already been further elucidated in said patent.

The actual destruction of pathogens, ISM and the AIDS virus is effectuated by injection of a suspension of these devices in distilled or deionized water with a non-reacting electrolyte directly, i.e. intravenously, into the bloodstream. A single injection is all that is required under these conditions. Accordingly, humans injected in this manner, upon being inspected after three weeks or more had elapsed and compared with similar humans that had been given placebos, were completely cured of AIDS. The control group still manifested AIDS. Accordingly, the tetrasilver tetroxide device performed in concert with and in full conformity with the ultimate objects of this invention. Furthermore, three out of four wasting syndrome terminal patients and four out of the five candidiasis terminal patients were still alive in 1995 after a year and a half had elapsed from their initial injection. By that time all the AIDS patients had been released from the clinic and allowed to return home.

Other objects and features of the present invention shall become apparent to those skilled in the art when the present invention is considered in view of the accompanying examples. It should, of course, be recognized that the accompanying examples illustrate preferred embodiments of the present invention and are not intended as a means of defining the limits and scope of the present invention.

EXAMPLE 1

Five patients afflicted with AIDS of the candidiasis etiological category were segregated for Tetrasil treatment. The rationale for selecting them was based on facts presented in an article by Peter H. Duesberg and Brian J. Ellison entitled "Is The AIDS Virus A Science Fiction?" (Policy Review, Summer 1990 pp. 40-51). Only the factual presentations of the article were utilized and the hypothesis of the authors was ignored. The facts presented in the article related to the method of selecting AIDS patients based on the five aforementioned etiological subgroups targeted by the CDC, and the evidence presented, that there is AIDS without HIV as well as with it so that an anti-viral agent in most instances will not necessarily restore the immunity system.

Evaluations with Tetrasil were conducted on AIDS patients at Lucha Contra el Sida, Comayaguela, Honduras. The patients two weeks prior to inoculation were removed from their AZT, AIDS therapy. Tetrasil was administered at approximately 40 PPM of blood volume per patient as a suspension in a proprietary buffer solution (pH=6.5), supplied by Holipharm Corporation.

The results of evaluations with candidiasis are tabulated in Table I under its disease category. All patients evaluated were terminal. Some, however, were in moderate (m) condition and others in poor (p) as designated in the Table. The I and F designations refer to initial and final values as shown. WBC indicates white cell blood count. The H column, following CD 8, indicates whether hepatomegaly occurred. This was an unfortunate consequence of the treatment which resulted in enlarged livers in all patients except the second one. Despite hepatomegaly, there was no interference with liver function.

The onset of hepatomegaly was not spontaneous and varied from patient to patient, being in the range of 4-16 days.

It should also be noted that shortly after injection of Tetrasil there were indications of fever (symbolized by T in the Ag.sub.4 O.sub.4 column), sometimes accompanied by fatigue (F). The body temperature was invariably 38.5.degree. C. (101.3.degree. F.). This was indicative of restoration of the immune response of the body, since normally the body will destroy pathogens when the immune system is functional by raising the temperature. The patient who died; first responded favorably to Diflucan, which previously gave no response. He was cured of his candidiasis, but unfortunately succumbed to his previous body damage. All the other candidiasis syndrome people who previously did not respond to the indicated medications subsequently responded after the Tetrasil treatment. Further evidence of the recovery of the AIDS patients manifested itself 30 days after the initial injection when white blood cell counts were taken. They are shown in Table I under the WBC column, which gives the initial and final WBC. All candidiasis patients showed a dramatic increase in their white blood cell counts, indicative of the restoration of their immunity systems.

EXAMPLE 2

The above protocol of Example 1 was repeated with AIDS patients exhibiting wasting syndrome. The results of their treatment are tabulated in Table I under the disease category of said syndrome. It should be noted that two of the four wasting syndrome patients showed improved white blood counts. The female patient, whose condition improved from poor and terminal to be among the living, showed a decrease in the WBC. However, she showed an increase in body temperature which was indicative of immune response. The test results indicate that one cannot rely on a single factor to indicate the demise of AIDS. The usual HIV marker CD 4 initial and final are irrelevant. ISM suppression appears to be more critical than the destruction of HIV. AIDS was suppressed, any permanent damage that had been done to the patients in the course of their succumbing to AIDS was not obviously cured or corrected by said crystal device treatment, rather said injury persisted and the patient was improved with respect to AIDS but still suffered from said permanent injury or impairment previously inflicted.


TABLE I
__________________________________________________ ________________________
Response of AIDS Patients to Single 40 PPM Ag.sub.4 O.sub.4 Inoculation
Date Weight
DISEASE
PATIENT Inoc.
WBC CD 4 DEATH
Lbs.
Group Sex
Age
Medictn
1994
I F I F CD 8
H 1944
I F Ag.sub.4 O.sub.4
__________________________________________________ ________________________
Candidiasis
M p
28 Diflucan
5/5
1,200
4,200
41
-- 221
+ 6/11
82 76
T
F m
33 " 5/5
6,000
6,700
554
872
394
- 98 98
T
F m
33 Ketaconzl
5/27
2,600
3,850
248
181
951
+ 123 123
T
M p
62 " 6/2
3,300
3,700
89
237
59
+ 105 92
F
F m
31 Pentamidn
6/2
2,400
3,050
9 181
65
+ 121 118
Pain
Wasting
M m
27 5/27
3,600
4,600
39
14
709
+ 119 120
T
Syndrome
M m
28 5/27
2,750
-- 10
-- 60
+ 7/19
121 119
T, F
F p
43 5/27
3,600
2,700
68
246
248
+ 101 98
T, F
M m
19 5/10
3,850
5,400
137
36
48
+ 103 106
T, F
__________________________________________________ ________________________



As this invention may be embodied in several forms without departing from the spirit or essential characteristics thereof, the present embodiments are therefore illustrative and not restrictive, since the scope of the invention is defined by the appended claims rather than by the description preceding them, and all changes that fall within the metes and bounds of the claims or that form their functional as well as conjointly cooperative equivalents, are therefore intended to be embraced by these claims.

[Nia Maishani]

^^^BUMP^^^